Literature DB >> 18613773

C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor.

Diana Wouters1, Ineke Wagenaar-Bos, Marieke van Ham, Sacha Zeerleder.   

Abstract

C1 inhibitor is a potent anti-inflammatory protein as it is the major inhibitor of proteases of the contact and the complement systems. C1-inhibitor administration is an effective therapy in the treatment of patients with hereditary angioedema (HAE) who are genetically deficient in C1 inhibitor. Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. In the present review we give an overview of the biology of C1 inhibitor and its use in HAE. Furthermore, we discuss C1 inhibitor as an experimental therapy in diseases such as sepsis and myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613773     DOI: 10.1517/14712598.8.8.1225

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  14 in total

1.  Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema.

Authors:  Didde Haslund; Laura Barrett Ryø; Sara Seidelin Majidi; Iben Rose; Kristian Alsbjerg Skipper; Tue Fryland; Anja Bille Bohn; Claus Koch; Martin K Thomsen; Yaseelan Palarasah; Thomas J Corydon; Anette Bygum; Lene N Nejsum; Jacob Giehm Mikkelsen
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

2.  Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses.

Authors:  Nguyen T Nguyen; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

Review 3.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

4.  A tick mannose-binding lectin inhibitor interferes with the vertebrate complement cascade to enhance transmission of the lyme disease agent.

Authors:  Tim J Schuijt; Jeroen Coumou; Sukanya Narasimhan; Jianfeng Dai; Kathleen Deponte; Diana Wouters; Mieke Brouwer; Anneke Oei; Joris J T H Roelofs; Alje P van Dam; Tom van der Poll; Cornelis Van't Veer; Joppe W Hovius; Erol Fikrig
Journal:  Cell Host Microbe       Date:  2011-08-18       Impact factor: 21.023

Review 5.  Current and emerging management options for hereditary angioedema in the US.

Authors:  Tolly G Epstein; Jonathan A Bernstein
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.

Authors:  Lakshmi C Wijeyewickrema; Emilie Lameignere; Lilian Hor; Renee C Duncan; Toshikazu Shiba; Richard J Travers; Piyushkumar R Kapopara; Victor Lei; Stephanie A Smith; Hugh Kim; James H Morrissey; Robert N Pike; Edward M Conway
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

Review 7.  Complement inhibitors to treat IgM-mediated autoimmune hemolysis.

Authors:  Diana Wouters; Sacha Zeerleder
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

8.  Conestat alfa for the treatment of angioedema attacks.

Authors:  Benjamin Davis; Jonathan A Bernstein
Journal:  Ther Clin Risk Manag       Date:  2011-07-01       Impact factor: 2.423

9.  The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial.

Authors:  Marjolein Heeres; Tjaakje Visser; Karlijn J P van Wessem; Anky H L Koenderman; Paul F W Strengers; Leo Koenderman; Luke P H Leenen
Journal:  Trials       Date:  2011-10-11       Impact factor: 2.279

Review 10.  Halting targeted and collateral damage to red blood cells by the complement system.

Authors:  M Jalink; E C W de Boer; D Evers; M Q Havinga; J M I Vos; S Zeerleder; M de Haas; I Jongerius
Journal:  Semin Immunopathol       Date:  2021-06-30       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.